Home / For clinicians / Conditions / Endocrinology
Endocrinology
1 condition and 3 prescribing guides so far.
By specialty and condition
Each condition page compares its drugs side by side and lists FDA decisions, label changes and open trials.
Prescribing guides
The first 90 days from the prescriber's side, built from the current label, the drugmaker's program and one public insurer policy.
Acromegaly
Palsonify (paltusotine)IGF-1 Titration and PA CriteriaNo REMS; specialty dispensing through Biologics by McKesson, Orsini or select pituitary centers after prior authorization; CrinetiCARE product enrollment form faxed to 844-CRN-FAXX (844-276-3299).Sandostatin LAR Depot (octreotide acetate)Switching and PA CriteriaNo REMS. Documented response to and tolerance of Sandostatin injection (at least 2 weeks for octreotide-naive patients, judged by GH and IGF-1); prior authorization, usually under the medical benefit; administration by a trained healthcare provider.Somatuline Depot (lanreotide)Titration and PA CriteriaNo REMS. IPSEN CARES enrollment started by the office with the patient's signed authorization; prior authorization; specialty pharmacy or buy and bill; administration by a healthcare provider in the office or another site of care.